Haemato-Biochemical Alterations following Doxorubicin Induced Cardio-Renal Toxicity and Amelioration by Hesperidin in Male Wistar Rats
DOI:
https://doi.org/10.48165/ijvsbt.22.5.21Keywords:
Doxorubicin, Haematological parameters, Hesperidin, Organ index, Serum biochemical parameters, Wistar ratAbstract
Doxorubicin is an effective anthracycline chemotherapeutic agent, but its clinical use is limited by dose dependent toxicity involving multiple organs, particularly the heart and kidneys. The present study was undertaken to evaluate the effects of doxorubicin on clinical manifestations, feed intake, body weight, organ index, haematological and serum biochemical parameters in Wistar rats and to assess the ameliorative potential of hesperidin in comparison with benazepril. Forty rats were randomly allocated into five groups of eight animals each. Group I served as control and received 0.5% carboxymethyl cellulose orally daily for 28 days. Groups II to V received doxorubicin intraperitoneally at 2.5 mg/kg body weight once weekly for four weeks. Group III additionally received benazepril at 10 mg/ kg/bw orally, while Groups IV and V received hesperidin orally at 100 mg/kg/bw and 200 mg/kg/bw body weight, respectively, daily for 28 days. Doxorubicin treated rats exhibited diarrhoea, lethargy, reduced locomotor activity, scruffy fur, chromodacryorrhoea, red urine, decreased feed intake, reduced terminal body weight, increased relative heart and kidney weights, anaemia, leukopenia, lymphopenia and significant increase in serum cholesterol, creatinine and blood urea nitrogen. Hesperidin ameliorated these alterations in a dose dependent manner, with the higher dose showing better protective efficacy. These findings indicate that hesperidin exerts substantial ameliorative effects against doxorubicin induced cardio-renal toxicity in Wistar rats.
Downloads
References
Abdel-Raheem, I. T., & Abdel-Ghany, A. A. (2009). Hesperidin alleviates doxorubicin-induced cardiotoxicity in rats. Journal of the Egyptian National Cancer Institute, 21(2), 175–184.
Alharbi, F. K., Alshehri, Z. S., Alshehri, F. F., Alhajlah, S., Khalifa, H. A., Dahran, N., & Ghonimi, W. A. (2023). The role of hesperidin as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: The antioxidant, anti-inflammatory, antiapoptotic, and cytoprotective potentials. Open Veterinary Journal, 13(12), 1718.
Arvi, Y., Wihandono, A., & Wibowo, M. D. (2025). The cardioprotective effects of bromelain on Wistar rat myocardial cells induced by doxorubicin: An evaluation based on troponin T and troponin I. Vascular and Endovascular Review, 8(19), 276–282.
Chaudhary, D., Khatiwada, S., Sah, S. K., Tamang, M. K., Bhattacharya, S., & Jha, C. B. (2016). Effect of doxorubicin on histomorphology of liver of Wistar albino rats. Journal of Pharmacy and Pharmacology, 4, 186–190.
Donia, T. I., Gerges, M. N., & Mohamed, T. M. (2018). Amelioration effect of Egyptian sweet orange hesperidin on Ehrlich ascites carcinoma (EAC) bearing mice. Chemico-Biological Interactions, 285, 76–84.
Ford, B., Dore, M., & Bartlett, B. (2023). Management of heart failure: Updated guidelines from the AHA/ACC. American Family Physician, 108(3), 315–320.
Fullerton, E. (2017). Doxorubicin: An overview. Today’s Veterinary Technician, 2(3), 24–34.
Kciuk, M., Gielecinska, A., Mujwar, S., Kołat, D., Kaluzinska-Kołat, Z., Celik, I., & Kontek, R. (2023). Doxorubicin—An agent with multiple mechanisms of anticancer activity. Cells, 12(4), 659.
Kondampati, R. D., Matukumalli, U. R., Borra, S., Beesam, S., & Debbarma, B. (2024). Haematological and serum biochemical evaluation of doxorubicin-induced toxicity in Wistar male rats and its amelioration with hesperidin. Journal of Animal Research, 14(2), 115–123.
Podyacheva, E., Shmakova, T., Kushnareva, E., Onopchenko, A., Martynov, M., Andreeva, D., & Toropova, Y. (2022). Modeling doxorubicin-induced cardiomyopathy with fibrotic myocardial damage in Wistar rats. Cardiology Research, 13(6), 339.
Sahu, B. D., Kuncha, M., Sindhura, G. J., & Sistla, R. (2013). Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine, 20(5), 453–460.
Sheibani, M., Azizi, Y., Shayan, M., Nezamoleslami, S., Eslami, F., Farjoo, M. H., & Dehpour, A. R. (2022). Doxorubicin-induced cardiotoxicity: An overview on pre-clinical therapeutic approaches. Cardiovascular Toxicology, 22(4), 292–310.
Soltani, H. A., Chenari, A., Alipanah, H., & Javanmardi, K. (2021). Protective effect of alamandine on doxorubicin-induced nephrotoxicity in rats. BMC Pharmacology and Toxicology, 22, 1–11.
Swamy, A. V., Gulliaya, S., Thippeswamy, A., Koti, B. C., & Manjula, D. V. (2012). Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian Journal of Pharmacology, 44(1), 73–77.
Syahputra, R. A., Harahap, U., Dalimunthe, A., Nasution, M. P., & Satria, D. (2022). The role of flavonoids as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: A review. Molecules, 27(4), 1320.
Urkude, A. P., Vihol, P. D., Patel, J. M., Patel, J. H., Varia, R. D., Sorathiya, V. L., & Dalvi, M. U. (2021). Chemopreventive efficacy of hesperidin against N-methyl-N-nitrosourea-induced mammary tumours in SD rats. International Journal of Current Microbiology and Applied Sciences, 10(6), 344–355.
Yakout, A., Husseina, S. A., Bakryb, S., & Thabita, M. (2021). Biochemical and haematological alterations associated with doxorubicin-induced toxicity in rat. Al-Azhar Bulletin of Science, 32(1), 11–16.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Indian Journal of Veterinary Sciences and Biotechnology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

